Amended Annual Report (10-k/a)
March 16 2023 - 4:38PM
Edgar (US Regulatory)
0001279704
false
--12-31
2022
FY
0001279704
2022-01-01
2022-12-31
0001279704
2022-06-30
0001279704
2023-03-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
Amendment No. 1
x |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 |
For the fiscal year ended December
31, 2022
¨ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 |
For the transition period from ______ to ______
Commission File Number 333-119366
CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
04-3321804 |
(State
or other jurisdiction of
incorporation or organization) |
|
(IRS Employer
Identification Number) |
|
|
100 Campus
Drive
Florham Park, New Jersey |
|
07932 |
(Address of principal executive
offices) |
|
(Zip Code) |
(608) 441-8120
(Registrant’s telephone number, including
area code)
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each
Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange
on Which Registered |
Common Stock, par value $0.00001 |
|
CLRB |
|
Nasdaq Capital Market |
Securities registered pursuant to Section 12(g) of
the Act:
None
Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No
x
Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject
to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”
and “emerging growth company” in Rule 12b-2 of the Exchange Act. Yes No
Large accelerated filer ¨ |
|
Accelerated filer |
¨ |
|
|
|
|
Non-accelerated filer x |
|
Smaller reporting company |
x |
|
|
|
|
|
|
Emerging growth company |
¨ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. ¨
If securities are registered pursuant to Section 12(b) of
the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an
error to previously issued financial statements. ¨
Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s
executive officers during the relevant recovery period pursuant to §240.10D-1(b). ¨
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x
The aggregate market value of the registrant’s
voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold,
or the average bid and asked price of such common equity, as of June 30, 2022, was $24,322,264.
As of March 3, 2023, there were 9,740,507
shares of the registrant’s $0.0001 par value common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant's definitive proxy statement for the registrant's 2023 Annual Meeting of Stockholders are incorporated by reference
in Part III of the annual report on Form 10-K. The definitive proxy statement will be filed with the U.S. Securities and Exchange Commission
within 120 days after the end of the fiscal year covered by the annual report on Form 10-K.
Auditor Name |
|
Auditor Location |
|
Auditor Firm ID |
Baker Tilly US, LLP |
|
Philadelphia, PA |
|
23 |
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A
(“Amendment No. 1”) is being filed to amend our Annual Report on Form 10-K for the year ended December 31,
2022 (the “Original Filing”), filed with the U.S. Securities and Exchange Commission on March 9, 2023 (the “Original
Filing Date”). The sole purpose of this Amendment No. 1 is to append Exhibits 3.9, 3.10, 10.18, 10.19, 10.29, 10.30, 10.31,
and 10.32, which were inadvertently omitted from the Original Filing, and to correct Exhibit 3.11 of the Original Filing. Except
as described above, no changes have been made to the Original Filing and this Amendment No. 1 does not modify, amend or update in
any way any of the financial or other information contained in the Original Filing. Part IV of the Original Filing is also amended
to add new certifications in accordance with Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.
PART IV
| Item 15. | Exhibits, Financial Statement Schedules. |
| (a) | Documents filed with this annual report on Form 10-K. |
| i. | All financial statements of the Company as set forth under Item 8 of the Original Filing. |
|
(2) |
Exhibits – The exhibits to this annual report on Form 10-K are listed on the Exhibit Index below. |
EXHIBIT INDEX
| |
| |
Incorporated by Reference |
Exhibit No. | |
Description | |
Form | |
Filing Date | |
Exhibit No. |
2.1 | |
Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated April 8, 2011 | |
8-K | |
April 11, 2011 | |
2.1 |
3.1 | |
Second Amended and Restated Certificate of Incorporation | |
8-K | |
April 11, 2011 | |
3.1 |
3.2 | |
Certificate of Ownership and Merger of Cellectar Biosciences, Inc. with and into Novelos Therapeutics, Inc. | |
8-K | |
February 13, 2014 | |
3.1 |
3.3 | |
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation | |
8-K | |
June 13, 2014 | |
3.1 |
3.4 | |
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation | |
8-K | |
June 19, 2015 | |
3.2 |
3.5 | |
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation | |
8-K | |
March 4, 2016 | |
3.1 |
3.6 | |
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation | |
8-K | |
June 1, 2017 | |
3.2 |
3.7 | |
Certificate of Amendment of Second Amended and Restated Certificate of Incorporation | |
8-K | |
July 13, 2018 | |
3.1 |
3.8 | |
Certificate of Amendment of Second Amended and Restated Certificate of Incorporation | |
8-K | |
February 25, 2021 | |
3.1 |
3.9 | |
Certificate of Correction of Certificate of Amendment of Second Amended and Restated Certificate of Incorporation | |
10-Q | |
May 10, 2022 | |
3.1 |
3.10 | |
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation | |
8-K | |
July 21, 2022 | |
3.1 |
3.11 | |
Amended and Restated By-laws | |
8-K | |
November 29, 2022 | |
3.1 |
3.12 | |
Form of Certificate of Designation of Series C Preferred Stock | |
S-1/A | |
July 18, 2018 | |
3.11 |
3.13 | |
Form of Certificate of Designation of Series D Preferred Stock certificate | |
8-K | |
December 28, 2020 | |
3.1 |
4.1 | |
Form of common stock certificate | |
S-1/A | |
November 9, 2011 | |
4.1 |
4.2 | |
Form of Series D Preferred Stock certificate | |
8-K | |
December 28, 2020 | |
4.1 |
4.3* | |
Description of Securities Registered under Section 12(b) of the Securities Exchange Act of 1934 | |
| |
| |
|
10.1 | |
Form of Restricted Common Stock Agreement** | |
10-Q | |
August 14, 2017 | |
10.1 |
10.2 | |
Form of Series D Common Stock Purchase Warrant | |
8-K | |
October 11, 2017 | |
4.1 |
10.3 | |
Registration Rights Agreement, dated as of October 10, 2017, by and among Cellectar Biosciences, Inc. and the Purchasers | |
8-K | |
October 11, 2017 | |
10.2 |
10.4 | |
Form of Non-Statutory Stock Option** | |
S-8 | |
November 9, 2017 | |
10.2 |
10.5 | |
Stock Option Agreement with James V. Caruso** | |
S-8 | |
November 9, 2017 | |
10.4 |
10.6 | |
Stock Option Agreement with Jarrod Longcor** | |
S-8 | |
November 9, 2017 | |
10.5 |
10.7 | |
Series E Common Stock Purchase Warrant | |
S-1/A | |
July 18, 2018 | |
4.5 |
10.8 | |
Form of Warrant Agency Agreement | |
S-1/A | |
July 18, 2018 | |
4.7 |
10.9 | |
Agreement of Lease between the Company and KBS II 100-200 Campus Drive, LLC | |
S-1/A | |
July 18, 2018 | |
10.35 |
10.10 | |
Form of Non-Statutory Stock Option (Definitive/Contingent – Employees)** | |
10-Q | |
November 13, 2018 | |
10.3 |
10.11 | |
Form of Non-Statutory Stock Option (Definitive/Contingent – Directors)** | |
10-Q | |
November 13, 2018 | |
10.4 |
10.12 | |
Amended and Restated Employment Agreement between the Company and James Caruso, dated April 15, 2019** | |
8-K | |
April 19, 2019 | |
10.1 |
10.13 | |
Amended and Restated Employment Agreement between the Company and Jarrod Longcor, dated April 15, 2019** | |
8-K | |
April 19, 2019 | |
10.2 |
10.14 | |
Form of Series F Common Stock Purchase Warrant | |
8-K | |
May 20, 2019 | |
4.1 |
10.15 | |
Form of Series G Common Stock Purchase Warrant | |
8-K | |
May 20, 2019 | |
4.2 |
10.16 | |
Registration Rights Agreement, dated as of May 16, 2019, by and among Cellectar Biosciences, Inc. and the Purchasers | |
8-K | |
May 20, 2019 | |
10.3 |
10.17 | |
Cellectar Biosciences, Inc. Amended and Restated 2015 Stock Incentive Plan** | |
8-K | |
June 14, 2019 | |
10.1 |
10.18 | |
2021 Stock Incentive Plan** | |
8-K | |
June 24, 2021 | |
10.1 |
10.19 | |
Amendment 1 to the 2021 Stock Incentive Plan** | |
8-K | |
June 27, 2022 | |
10.1 |
10.20 | |
Amendment to Amended and Restated Employment Agreement between the Company and Jarrod Longcor dated November 10, 2019** | |
10-Q | |
November 12, 2019 | |
10.2 |
10.21 | |
Form of Underwriting Agreement | |
S-1/A | |
May 20, 2020 | |
1.1 |
10.22 | |
Form of Series H Warrant | |
S-1/A | |
May 20, 2020 | |
4.3 |
10.23 | |
Form of Warrant Agency Agreement | |
8-K | |
June 5, 2020 | |
4.3 |
10.24 | |
Equity Distribution Agreement between Cellectar Biosciences, Inc. and Oppenheimer & Co. Inc., dated August 11, 2020 | |
8-K | |
August 11, 2020 | |
10.1 |
10.25 | |
Form of Securities Purchase Agreement | |
8-K | |
December 28, 2020 | |
10.1 |
10.26 | |
Form of Registration Rights Agreement | |
8-K | |
December 28, 2020 | |
10.2 |
10.27 | |
Employment Agreement between the Company and Chad Kolean, dated February 23, 2022 | |
8-K | |
February 25, 2022 | |
10.1 |
10.28* | |
Form of First Amendment of Lease, dated December 30, 2022 | |
8-K | |
January 4, 2023 | |
|
10.29 | |
Form of Common Warrant | |
8-K | |
October 25, 2022 | |
|
10.30 | |
Form of Pre-Funded Warrant | |
8-K | |
October 25, 2022 | |
|
10.31 | |
Form of Registration Rights Agreement, dated as of October 20, 2022, by and between the Company and the purchasers named therein | |
8-K | |
October 25, 2022 | |
|
10.32 | |
Form of Indemnification Agreement | |
8-K | |
December 2, 2022 | |
|
21.1* | |
List of Subsidiaries | |
| |
| |
|
23.1* | |
Consent
of Independent Registered Public Accounting Firm (Baker Tilly US, LLP, Philadelphia, PA, PCAOB ID: 23) | |
| |
| |
|
24.1* | |
Power of Attorney (included on the Signatures page of this Annual Report on Form 10-K) | |
| |
| |
|
31.1 | |
Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| |
| |
|
31.2 | |
Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| |
| |
|
32.1* | |
Certification of chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| |
| |
|
101* | |
Interactive Data Files | |
| |
| |
|
104* | |
Cover Page Interactive Data File | |
| |
| |
|
| |
| |
| |
| |
|
*Previously filed with the Original Filing.
** Management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused Amendment No. 1 to this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
CELLECTAR BIOSCIENCES, INC. |
|
|
|
|
By: |
/s/ James V. Caruso |
|
James V. Caruso |
|
Title: Chief Executive Officer |
|
March 16, 2023 |
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2023 to Jul 2024